Study of Serum Hyperamylasemia After Pancreatectomy and Its Effects on Recovery and Patient Safety

What this Trial Is About

Researchers are studying patients who have undergone pancreatectomy to understand the role of postoperative hyperamylasemia POH as a predictor of complications after surgery. The study aims to assess biochemical changes after pancreatectomy and to improve the definition and classification of postpancreatectomy acute pancreatitis PPAP as established by the International Study Group of Pancreatic Surgery ISGPS. This observational study seeks to provide insights for better early management of postoperative complications. Participants are patients who have undergone pancreatic resection for either malignant or benign diseases. Blood samples will be collected before surgery, during the operation at specific times, and postoperatively on days 1, 2, 3, 5, and 7 to measure amylase, lipase, and several other laboratory parameters including leucocytes, CRP, bilirubin, transaminases, and interleukin-6. Intraoperative collection of pancreas juice will also be analyzed. Patients will be followed during their hospital stay and at 3 and 6 months after discharge to record clinical outcomes such as complications and any need for rescue pancreatectomy. Throughout the study, participants will undergo multiple blood tests and clinical assessments to monitor their biochemical status and postoperative recovery. Researchers will evaluate the incidence of PPAP and the significance of biochemical changes within 90 days after surgery. Secondary measures include correlations of hyperamylasemia with rescue pancreatectomy, radiological findings, and postoperative mortality. Safety and patient outcomes will be closely monitored during the follow-up period extending up to six months post-discharge, with total participation lasting several months from surgery through follow-up visits.

Incidence and Clinical Impact of Serum Hyperamylasemia (POH) After Pancreatectomy on Postoperative Outcome and Patient Safety